CA2082808A1 - Osmotically driven syringe - Google Patents
Osmotically driven syringeInfo
- Publication number
- CA2082808A1 CA2082808A1 CA002082808A CA2082808A CA2082808A1 CA 2082808 A1 CA2082808 A1 CA 2082808A1 CA 002082808 A CA002082808 A CA 002082808A CA 2082808 A CA2082808 A CA 2082808A CA 2082808 A1 CA2082808 A1 CA 2082808A1
- Authority
- CA
- Canada
- Prior art keywords
- osmotic
- wall
- syringe
- solute
- engine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003204 osmotic effect Effects 0.000 claims abstract description 108
- 239000012530 fluid Substances 0.000 claims abstract description 56
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 54
- 230000009286 beneficial effect Effects 0.000 claims abstract description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims description 35
- 229920002301 cellulose acetate Polymers 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 14
- -1 polypropylene Polymers 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 9
- 229920003023 plastic Polymers 0.000 claims description 8
- 239000004033 plastic Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000004743 Polypropylene Substances 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 150000002739 metals Chemical class 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 2
- 239000011521 glass Substances 0.000 claims description 2
- 238000005086 pumping Methods 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 15
- 239000012229 microporous material Substances 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 2
- 239000010410 layer Substances 0.000 description 32
- 239000012528 membrane Substances 0.000 description 28
- 239000002357 osmotic agent Substances 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 8
- 238000007906 compression Methods 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 230000035699 permeability Effects 0.000 description 4
- 239000004417 polycarbonate Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000011976 maleic acid Substances 0.000 description 3
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- YZBOVSFWWNVKRJ-UHFFFAOYSA-M 2-butoxycarbonylbenzoate Chemical compound CCCCOC(=O)C1=CC=CC=C1C([O-])=O YZBOVSFWWNVKRJ-UHFFFAOYSA-M 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- IDLSITKDRVDKRV-XHXSRVRCSA-N Ritodrine hydrochloride Chemical compound Cl.N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IDLSITKDRVDKRV-XHXSRVRCSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- RFUZHZOLHOAGIX-UHFFFAOYSA-N acetic acid;2-chloroacetic acid Chemical compound CC(O)=O.OC(=O)CCl RFUZHZOLHOAGIX-UHFFFAOYSA-N 0.000 description 1
- JVIUIOWKTNJXAJ-UHFFFAOYSA-N acetic acid;2-ethoxy-2-oxoacetic acid Chemical compound CC(O)=O.CCOC(=O)C(O)=O JVIUIOWKTNJXAJ-UHFFFAOYSA-N 0.000 description 1
- YMNMXQILQOXZPB-UHFFFAOYSA-N acetic acid;4-methylbenzenesulfonic acid Chemical compound CC(O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 YMNMXQILQOXZPB-UHFFFAOYSA-N 0.000 description 1
- WOOJRPBCEMEHLS-UHFFFAOYSA-N acetic acid;butane-1-sulfonic acid Chemical compound CC(O)=O.CCCCS(O)(=O)=O WOOJRPBCEMEHLS-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- GJAYYEWRFJQMQK-UHFFFAOYSA-N acetic acid;ethyl carbamate Chemical compound CC(O)=O.CCOC(N)=O GJAYYEWRFJQMQK-UHFFFAOYSA-N 0.000 description 1
- CBICCXFXCXELAR-UHFFFAOYSA-N acetic acid;ethyl hydrogen carbonate Chemical compound CC(O)=O.CCOC(O)=O CBICCXFXCXELAR-UHFFFAOYSA-N 0.000 description 1
- ZXPJBQLFCRVBDR-UHFFFAOYSA-N acetic acid;methanesulfonic acid Chemical compound CC(O)=O.CS(O)(=O)=O ZXPJBQLFCRVBDR-UHFFFAOYSA-N 0.000 description 1
- MFOPEVCFSVUADB-UHFFFAOYSA-N acetic acid;methyl carbamate Chemical compound CC(O)=O.COC(N)=O MFOPEVCFSVUADB-UHFFFAOYSA-N 0.000 description 1
- 229920006397 acrylic thermoplastic Polymers 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001062 anti-nausea Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960004395 bleomycin sulfate Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001425 deferoxamine mesylate Drugs 0.000 description 1
- IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical compound [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960000807 dihydroergotamine mesylate Drugs 0.000 description 1
- ADYPXRFPBQGGAH-UMYZUSPBSA-N dihydroergotamine mesylate Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-UMYZUSPBSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229960001410 hydromorphone Drugs 0.000 description 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004715 morphine sulfate Drugs 0.000 description 1
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 229920001483 poly(ethyl methacrylate) polymer Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000012254 powdered material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 229960001634 ritodrine Drugs 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960005105 terbutaline sulfate Drugs 0.000 description 1
- KFVSLSTULZVNPG-UHFFFAOYSA-N terbutaline sulfate Chemical compound [O-]S([O-])(=O)=O.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1.CC(C)(C)[NH2+]CC(O)C1=CC(O)=CC(O)=C1 KFVSLSTULZVNPG-UHFFFAOYSA-N 0.000 description 1
- OKUCEQDKBKYEJY-UHFFFAOYSA-N tert-butyl 3-(methylamino)pyrrolidine-1-carboxylate Chemical compound CNC1CCN(C(=O)OC(C)(C)C)C1 OKUCEQDKBKYEJY-UHFFFAOYSA-N 0.000 description 1
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 1
- ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M2005/14513—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons with secondary fluid driving or regulating the infusion
Abstract
An implantable osmotically driven syringe (20) is disclosed which can be used to deliver a beneficial agent, such as a drug, at a predetermined rate over an extended period of time. A movable piston (24) divides the syringe (20) into a beneficial agent-containing compartment (23) and a driving compartment (26). The piston (24) is movable into a position wherein the driving compartment (26) has an unoccupied volume of essentially zero. The syringe (20) is driven by an osmotic engine (10) which has a shaped wall (12) surrounding, and in contact with, an osmotic solute (17). The wall (12) is comprised of a semipermeable and/or microporous material which is permeable to the external fluid (e.g., water) but is impermeable to the solute (17). The engine (10) also has a passageway (13) forming a fluid flow path between the osmotic solute (17) and the driving compartment (26). A portion of the wall (12) is exposed to a fluid-containing external environment. At least about 30 % of the wall (12) which contacts the solute (17) also is exposed to the fluid in the external environment. In operation, water from the external environment is imbibed through the semipermeable wall (12) forming a solution of the solvent (17) in the osmotic engine (10). As fresh incoming fluid from the external environment is imbibed by the engine (10), the solution is pumped through the passageway (13) into the driving compartment (26). The pumping action drives the piston (24) which causes the beneficial agent to be delivered by the syringe (20).
Description
W O 93/00954 PC~r/US91/04684 2~s~n~ .
OSMOTICALLY DRIVEN SYRINGE
TECHNICAL FIELD
' s The invention pertains to a novel and useful osmotically driven syringe and in particular an implantable osmotically driven syringe.
The syringe delivers a beneficial agent, such as a drug, to an environment of use, such as an animal body.
,: ' ' o BACKGROUND ART
Over the past decade, much research has been devoted to developing new and useful devices for delivering beneficial agents to agent receptor environments of use. For example, in United States Patent No. 3,760,984 issued to Theeuwes, there is disclosed an osmotic delivery device comprising an inner collapsible container carrying on its outer surface a layer of an osmotic solute and a surrounding layer of a polymer permeable to fluid and impermeable to solute. In United States Patent No. 3,971,376, issued to Wichterle, ; 20 a device is disclosed comprising a capsule having a unitary wall `
formed of a substantially noncollapsible elastic material that maintains a constant volume and which is adapted to be implanted :.! subcutaneously.
' 25 In United States Patent No. 3,g87,790 issued to Eckenhoff et '~ al., there is dlsclosed another osmotic delivery device which contains an outer shape-retaining membrane which surrounds a solute ; layer which in turn surrounds a collapsible bag containing a liquid drug. Water from the exterior environment permeates through the .~ 30 outer membrane into the solute layer, causing the solute layer to swell. The swelling forces the bag to collapse and deliver the drug through a delivery orifice. United States Patent No. 3,995,631 issued to Higuchi et al., discloses a similar device (Figure 4) comprising an inner flexible bag containing a drug formulation. The 35 bag separates the drug from an osmotically effective solute material.
Both the drug and the solute are contained within a housing having an :' ~
. .
:. ''.
' ' ' ' ' , . ' ' : ' ' ` ' . ~ : . ` `: .:: ! : ' ' . ' , . . '. ' : ~ . ' . . ' ': ' ' . ' WO 93/00954 ~ PC~/US91/04684 exterior wall that is, at least in part, semipermeable. U.S. Patent No. 3,995,632 issued to Nakano et al discloses a similar device which incorporates a movable barrier within the housing. The barrier divides the housing into two compartments, one containing the solute s and the other containing the drug. The solute-containing compartment has an exterior wall that is, at least in part, semipermeable. The solute-containing compartment acts as an osmotic driver for the device.
~ lo U.S. Patent No. 4,410,328 issued to Theeuwes discloses an ; osmotically driven pump. The pump includes a housing 11 and a slidable piston 14 which divides the interior of the housing into two compartments. The first compartment contains a liquid drug 13 while the second compartment contains an osmotic driver 17. The osmotic s driver is a tablet of an osmotically effective solute, such as sodium chloride, which is coated with a semipermeable wall material. A
delivery orifice 20 is drilled through the semipermeable wall. The bottom surface of the osmotic driver 17 is exposed to water from the external environment. This can be done by incorporating a screen, or zo a plurality of holes through retaining member 18, immediately below the osmotic driver 17. Water from the external environment then contacts and is imbibed through the semipermeable wall 23 into the osmotic driver 17 to form a solution of the osmotic solute. As water continues to be imbibed through the semipermeable wall, the solution 2s in the driver is pumped through delivery orifice 20. The pumped solution eventually fills the space between the osmotic driver 17 and the bottom of piston 14. Thereafter, further pumping of solution from driver 17 forces piston 14 to more forward in housing ll. As the piston moves towards the opening 15, it urges a beneficial agent, 30 such as a drug, out of the compartment 13.
The device illustrated in U.S. Patent 4,410,328 has several potential disadvantages when used as an implantable pump. First, there is a substantial delay between the time when the osmotic driver : 3s 17 is exposed to the external aqueous environment (i.e., implanted in the body) and the time when the pump begins dispensing drug. This " .. . - . . . ~ . .
.
.. .. . . .... . .
: ~ : . . ' ' . ' ' ., ' , ' '' , . ' ' . . , :' , - . ~ . ~ , , ., .
.. . .. , . : ~ . , WO 93~00954 PCI/US91/04684 2~82~0~
delay is in part caused by the space surrounding the driver which must first be filled with solution pumped from the driver before the piston is forced to move forward. Secondly, only the bottom surface of osmotic driver 17 is exposed to the external aqueous environment.
s Because only a relatively small portion (i.e., about 25% or less) of the membrane surface area is exposed to the external aqueous environment, the rate at which water is imbibed through the semipermeable wall 23, and therefore the rate at which the drug is delivered by the pump, is difficult to control. This is especially critical with osmotically driven pumps which are implanted in an animal body. When implanted in certain animal tissues, portions of - the external surface of the pump will not be exposed to water. Thus, a dispensing device which utilizes an osmotic engine having only a small surface area of microporous and/or semipermeable membrane exposed will tend to have a greater degree of variability in its drug delivery rate since part or all of the membrane may not be exposed to aqueous body fluids.
.
While the above-described devices are useful for delivering : 20 many agents, and while they represent a valuable contribution to the delivery art, there has been a need in the art for an osmotically driven syringe which begins delivering a drug or other beneficial agent as soon as the syringe is placed in an aqueous environment (i.e., with a minimal lag time between the time when the syringe is 25 placed in the aqueous environment and the time when the syringe begins delivering the beneficial agent).
It is another object of the present invention to provide an osmotically driven syringe which can delivery a beneficial agent, 30 such as a drug, at a more uniform and more predictable delivery rate than was achieved by the osmotically driven syringes of the prior art.
In particular, it is an object of the present invention to 3s provide an osmotically driven syringe having the above-described .
.. . ~ .. . . . . , ............ , , . ....... ;, . . . . . ~
: ; . . . :~, ,, , ~ -2 ~
features and having a size making it suitable for implantation in an ~ animal body and in particular for implantation in a human body.
; DISCLOSURE OF THE INYENTION
The present invention provides an osmotically driven dispensing device for delivering a beneficial agent to an environment of use.
The device comprises a syringe having a chamber with a movable piston therein, the piston dividing the chamber into a beneficial agent-containing compartment and a driving compartment. The piston is movable into a position wherein the piston occupies substantially all of the driving compartment. The device includes an osmotic engine attached to the syringe adjacent the driving compartment. The osmotic engine comprises a shaped wall surrounding, and in contact with, an osmotic solute. The shaped wall has an external surface exposed to a fluid in an external environment and a passageway providing a fluid flow path between the osmotic solute and the driving compartment. The shaped wall is comprised of a material that is permeable to the external fluid and has a sufficient degree of 'I 20 impermeabillty to the solute to generate an osmotic pressuredifferential across the wall when exposed to the external fluid. At least about 30% of the wall which is in contact with the osmotic solute is also exposed to the external fluid. Preferably, at least about 50% of the wall which is in contact with the osmotic solute is 2s also exposed to the external fluid. Most preferably, substantially all of the wall which is in contact with the osmotic solute is also exposed to the external fluid.
Preferably, the osmotic engine comprises a shaped wall 30 surrounding a layer of an osmotically effective solute and a layer of a rigid non-dissolving material. The rigid non-dissolving layer provides support for the wall and maintains the wall shape adjacent the driving compartment. The wall preferably comprises a thin membrane that is permeable to the externa1 fluid (e.g., water) and .~ 3s substantially impermeable to the solute. A passageway is provided through both the wall and the rigid non-dissolving layer, thereby :
'.,;' ' '. '' ` ','.'. ~; ` ' ', ', ,- ,. ~ ~
:., , . . , . . , :
w o 93/00954 PCT/US91/0~684 ~23~
providing a fluid flow path between the osmotic solute layer and the driving compartment.
In operation, the external fluid is imbibed through the wall s into the osmotic engine forming a solution of the osmotic solute.
The solution is pumped through the passageway into the driving compartment as fresh fluid is imbibed through the wall. The pumped solution exerts pressure on the piston, forcing the piston to move within the syringe and deliver the beneficial agent from the o beneficial agent-containing compartment to the environment of use.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a cross sectional view of an osmotically driven s syringe utilizing a bilayered osmotic engine according to the present invention;
Figure Z is an enlarged cross sectional view of the osmotic engine shown in Figure li Figure 3 is a cross sectional view of a single layer osmotic engine suitable for use with the syringe illustrated in Figure 1;
Figure 4 is a cross sectional view of another embodiment of a 25 bilayered osmotic engine suitable for use according to the present invention;
i Figure 5 is a cross sectional view of the posterior end of an osmotically driven syringe utilizing the bilayered osmotic engine 30 illustrated in Figure 4;
Figure 6 is a graph showing the volume of a liquid beneficial agent delivered over a period of about 50 hours by an osmotically driven syringe utilizing the osmotic engine illustrated in Figure 3;
~s and .~ . ; .. : , ~ ` . . . . .. . . .
2 ~ ~ 2~ 6 Figure 7 is a graph showing the volume of a liquid beneficial agent delivered over a period of about 160 hours by an osmotically driven syringe utilizing the osmotic engine illustrated in Figure 2.
s In the drawings and specification, like parts in related Figures are identified by like numbers.
.: , MODES FOR CARRYING OUT THE INVENTION
" .
o Figure 1 of the drawings illustrates one example of a new and useful osmotically driven syringe for dispensing a liquid beneficial agent and Figures 2-4 illustrate three different embodiments of osmotic engine 10. Figure 4 illustrates another embodiment of a , bilayer osmotic engine which can be used with the syringe illustrated in Figure 5 having a cylindrically shaped housing.
The osmotic engine is designated in the Figures by the numeral 10. Osmotic engine 10 comprises a semipermeable or microporous wall 12 that encapsulates a tablet 16 of an osmotic agent represented by 17. A passageway 13 through semipermeable wall 12 provides a path for a solution of solute 17 to flow out of osmotic engine 10.
~ Referring to Figure 1, the syringe 20 is comprised of a housing h 22, which forms an interior chamber 21 having a movable piston 24 2s therein. The chamber 21 is divided by piston 24 into a beneficial agent-containing compartment 23 and a driving compartment 26. The piston 24 is movable into a position abutting against the engine 10, whereby the piston 24 occupies substantially all of the driving compartment 26. In this position the driving compartment 26 has an 30 "unoccupied" volume of essentially zero and the beneficial agent-containing compartment 23 has a maximum volume.
.'' The initial zero volume feature of compartment 26 has several benefits. First, the lag time for the syringe 20 to begin pumping 3s the beneficial agent from compartment 23 is minimized. This feature is important in those instances where it is desired to have syringe .,1 .
.
.` .
w o 93/00~54 PCT/US9l/0~684 7 ~ (~ ~ ~ n ~
20 begin delivering beneficial agent as soon as possible after the syringe 20 is placed in the fluid containing environment of use. The prior art osmotically driven pumps, such as the one disclosed in U.S.
Patent No. ~,410,328 typically had an initial lag period on the order s of about 10 to about 15 hours depending upon the size of the pump.
In the osmotically driven syringe of the present invention, the lag period has been reduced by about 70% thereby providing a lag period of only about 3 to about 5 hours for equivalently sized pumps/syringes. Second, compartment 26 contains substantially no o air. This is desirable because any air initially trapped in compartment 26 will cause a certain amount of pressure fluctuation on the piston 24 once osmotic engine I0 begins pumping solution. These pressure fluctuations cause variations in the delivery rate of syringe 20. Third, air initially trapped within chamber 26 creates a s potential hazard in intravenous drug delivery applications since the trapped air can leak into the beneficial agent-containing compartment 23. In the present invention, this potential ha~ard is e1iminated.
Syringe 20 also has a delivery port 25 which can be shaped to 20 accept a hypodermic needle, an IV catheter or the like. Piston 24 fits snugly against the internal surface of housing 22 and forms a fluid tight seal between compartment 23 and compartment 26. Piston ~
24 may be made of rubber, nylon, polytetrafluoroethylene and the :
like. Likewise, the housing 22 may be made from well known materials 25 such as metals or plastics that are inert relative to the liquids they contact and are nonirritating to an animal body. Examples of suitable materials include stainless steel, aluminum, polyolefins such as polypropylene and polyethylene, polyesters, polyamides, and polycarbonates. Of these, polypropylene is preferred.
The osmotic engine 10 is sealed within the posterior end portion 28 of syringe 20. The interior surface of end portion 28 is bevelled as shown in Figure 1. The osmotic engines 10 illustrated in Figure 2 and 3 are correspondingly shaped to closely fit against the 35 bevelled surface of end portion 28 and form a fluid tight seal therewith.
.: . . : ', ' ' - ' ' . 2 a ~ 8 Of course, it is within the scope of the present invention to utilize a syringe housing having other shapes. For instance, the interior surface of end portion 28 may be cylindrically shaped with no bevelling. As shown in Figure 5, the interion surface of end s portion 28 is threaded and adapted to receive a threaded cap 27.
The inner surface of cap 27 is cylindrically shaped to receive an osmotic engine 10 as shown in Figure 4 with the outer diameter of engine 10 closely approximating the inner diameter of cap 27. The osmotic engine 10 may be secured within cap 17 using an adhesive. An o 0-ring 29 may optionally be provided to ensure a fluid tight seal between cap 27 and syringe housing 22. Cap 27 may be made from the materials used to make housing 22 or the materials used to make membrane 12. Preferably, cap 27 is made from polystyrene, polyvinylchloride, polyacetal, polymethyl methacrylate~ cellulose acetate or cellulose acetate butyrate.
The osmotic engine 10 may be secured to the end portion 28 of syringe 20 (or to cap 27) by conventional means. For example, the osmotic engine 10 may be attached to housing 22 (or to cap 27) using 20 an adhesive which can adhere to the material used to construct the syringe (typically plastic) and the material used to form the semipermeable wall 12 (typically a cellulosic polymer). When utilizing a plastic housing 22 (or a plastic cap 27) and a cellulosic wall 12, pharmaceutically acceptable acrylic-based adhesives are 2s preferably used. It is important to orient osmotic engine 10 with the passageway 13 opening into compartment 26.
Wall 12 is preferably comprised of a membrane that possesses permeability to an external fluid such as water while simultaneously 30 possessing some degree of impermeability to osmotic agent 17, typically a salt or sugar. Wall 12 can be formed of a semipermeable material that has uniform properties across all its dimensions, that is, it is substantially imperforate or substantially homogenous.
Alternatively, wall 12 can be formed of a microporous material, that 3s is, a material having micropores or microholes. Furthermore, wall 12 can be formed of a material that is both semipermeable and WO 93/00954 PCI/US91/0~68~
9 2~2~
microporous, allowing an external fluid to permeate through while remaining substantially impermeable to osmotic agent 17. When wall 12 ls comprised of a material that is substantially imperforate, molecules of the external fluid dissolve in and diffuse through wall s 12 and into engine 10. When wall 12 is comprised of a microporous material, molecules of the external fluid migrate and diffuse into the micropores, then into engine 10. When wall 12 is comprised of a material having both of these properties, external fluid enters engine 10 by a concurrent operation of each of these mechanisms, that is, by osmosis through wall 12 and by diffusion through the pores of wall 12.
As shown in Figures 1 and 5, a portion of wall 12, the portion designated 12a, is exposed to the external environment while a second s portion of wall 12, designated 12b, is sealed within the syringe housing 22 and thus is not exposed to the external environment. As is clearly shcwn in Figures 1 and 5, the interior surfaces of wall portion 12a are in contact with the tablet 16 of osmotic agent 17.
In the most preferred embodiments illustrated in Figures 1 and 5, 20 substantially all of the wall portion 12a which is exposed to the external fluid is also in contact with the osmotic agent 17.
; ~owever, it is also within the scope of the present invention to utilize an osmotic engine in which at least 30% of the wall portion which is in contact with the osmotic solute along its interior 2s surface is also exposed to the external environment along its exterior surface. More preferably, at least about 50% of the wall portion which is in contact with the osmotic solute along its interior surface is also exposed to the external environment along its exterior surface. By maximizing the wall surface area exposed to 30 the external environment, the variability in the pumping rate of osmotic engine 10 is reduced.
Preferably, as shown in Figures 1, 2 and 4, the osmotic engine has a bilayered configuration including a layer of an osmotic : 3s agent 17 and a second layer 14 comprised of a rigid non-dissolving material. The layer 14 may be comprised of any rigid, non-dissolving .. . . . . . . . .
... .. .. . .
WO 93/00954 PCrIUS91/04684 ~ a ~ 2 ~ o material such as rigid plastics, ceramics, glasses and/or metals.
Preferably, layer 14 is comprised of a sterilizable, inert material.
Most preferably, layer 14 is comprised of a powdered material that becomes rigid after compression. Examples of non-dissolving powdered ; materials that become rigid after compression include powdered micropolyethylene wax and powdered calcium diphosphate. Generally, because the material forming layer 14 is non-dissolving, it will have little or no osmotic activity. In the most preferred embodiments shown in Figures 1 and 5, the wall portion 12b has an interior surface that is in direct contact with layer 14 and not in direct . contact with agent 17. On the other hand, substantially all of the wall portion 12a has an interior surface which is in contact with the osmotic agent 17. Thus in the most preferred embodiments illustrated in Figures 1 and 5, substantially all portions of wall 12 having an osmotic concentration gradient there-across, are also exposed to the exterior environment.
In the embodiment illustrated in Figure 3, the osmotic engine 10 has a single layer configuration. The osmotic agent 17, ; 20 optionally mixed with binders and/or buffers, is compressed to form atablet 16. The compression step may be performed in a conventional tablet making machine. The tablet 16 is then coated with a solution of a suitable semipermeable/microporous film forming material in accordance with known methods to form the semipermeable/microporous zs wall 12. Lastly, the passageway 13 is drilled into one side of osmotic engine 10 using a drill, laser or other known technique.
The b~layered osmotic engine 10 illustrated in Figures 1, 2, 4 and 5, may be formed by concurrently compressing a layer of a 30 suitable osmotic agent 17, optionally mixed with binders and/or buffers, and a layer 14 of a non-dissolving material which hardens upon compression. The compression step may be conducted in a conventional tablet making machine to form the bilayered tablet 16 having the structures illustrated in Figures 2 and 4. ~he bilayered 35 tablet 16 is then coated with a solution of a suitable semipermeable/
microporous film forming material in accordance with known methods to :
~82~"
form the semipermeable/microporous wall 12. Lastly, the passageway 13 is drilled into one side of osmotic engine 10 using a drill, laser or other known technique. When drilling a bilayered tablet 16, the passageway 13 is drilled in the side of the tablet 16 having the s rigid non-dissolving layer 14. It is important to drill the passageway 13 completely through layer 14 in order to provide an open fluid flow path which enables the solution of osmotic agent 17 to be pumped through passageway 13 to the drivjng compartment 26 of the syringe 20.
10 . .
Because layer 14 is composed of a rigid non-dissolving material, its structural integrity is not affected by the pumping of fluid through osmotic engine 10. As the agent 17 within osmotic engine 10 is dissolved, the layer 14 provides a rigid structural support for the wall portion 12b which is attached to syringe 20.
Thus, even as the active agent 17 is dissolved and pumped out of engine 10, the layer 14 retains its original shape and therefore wall portion 12b remains sealed to syringe 20.
.
Typical materials for forming wall 12 include synthetic or naturally occurring semipermeable and/or microporous membranes known to the art as osmosis and reverse osmosis membranes. Preferably, wall 12 is comprised of a cellulose ester. ~xamples of suitable membrane materials include commercially available unplasticized 25 cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose nitrate with 11% nitrogen, cellulose diacetate, cellulose triacetate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, cellulose acetate, acetaldehyde dimethyl acetate, cellulose acetate ethyl carbamate, 30 cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulfonate, cellulose acetate butyl sulfonate, cellulose acetate propionate, 3s cellulose acetate p-toluene sulfonate, triacetate of locust gum bean, cellulose acetate with acetylated hydroxyethyl cellulose, WO 93/00954 PCr/US91/04684 2 ~
hydroxylated ethylene-vinylace~ate, cellulose acetate butyrate having a viscosity of from about 10 seconds to about 50 seconds, cellulose acetate butyrate containing about 17 percent o~ combined butyryl and about 29.5 percent acetyl, cellulose acylate, cellulose diacylate, s cellulose triacylate, permselective, aromatic nitrogen-containing polymeric membranes that exhibit water permeability and essentially no solute passage, osmosis membranes made from polymeric epoxides, osmosis membranes made from copolymers of an alkylene oxide and alkyl glycidyl ether, semipermeable polyurethanes, semipermeable o polyglycolic or polylactic acid and derivatives thereof, thin film membranes as disclosed by Loeb and Sourirajan in United States Patent No. 3,133,132, the membranes of ionically associated polyelectrolytes, the polymers formed by the coprecipitation of polycation and a polyanion as described in United States Patents 3,276,586; 3,541,005; 3,541,006; 3,546,142; 3,173,876; derivatives of polystyrene such as poly(sodium styrenesulfonate) and poly(vinylbenzyl^trimethyl-ammonium chloride), and the like. Wall 12 may also be formed from a microporous membrane such as polysulphone, polyvinyl chloride, polystyrene, nylon, polycarbonate, polymethyl 20 methacrylate, and other materials using soluble pore forming agents.
Generally, membranes having an osmotic fluid permeability of loB to 10~9 cm2/atm/hr against a saturated solute solution at the temperature ` of use while simultaneously possessing a sufficient degree of impermeability to the solute to generate an osmotic pressure 2s d~fferent1al across the membrane are useful and within the spirit of the invention.
Semipermeable wall 12 may also contain a wall forming pharmaceutically acceptable polymer or agent which acts as a 30 permeability enhancer to aid the passage of fluid into the osmotic engine 10. Representative of polymers and agents for the present purpose include water soluble and/or swellable polymers such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl ce~lulose, ethyl methylcellulose, methylcellulose, acrylics including 35 polyacrylic acid, polyethyl methacrylate, polymethyl methacrylate, . pyrrolidones including polyvinyl pyrrolidone, alkylated ' ~:
., .~, .
Wo 93/0095~ P~r/US91/04684 13 2~2'~,~Y`
vinylpyrrolidone polymers, poly(vinylpyrrolidone/vinyl acetate) copolymers, vinylpyrrolidone/dimethylamino-ethylmethacrylate copolymers, maleic acid polymers such as monobutyl ester of : poly(methyl vinylether/maleic acid), monoethyl ester of s poly(methylvinyl ether/maleic acid), poly(methylvinylether/~aleic anhydride) copolymer, polyvinyl alcohol hydrolyzed 75 to 85%, ~a~er soluble agents such as polyethylene glycol, polyethylene oxide, guar gum, gum arabic, dextran, citric acid, triethyl citrate, acetyltriethyl citrate, sucrose, fructose, glycerin, tria~etin, and o the like.
Various osmotically effective solutes which can be used as the osmotic agent 17 include solutes and hydrophilic polymers. Suitable hydrophilic polymers include those described in U.S. Patent No.
IS 4,327,775. Suitable solutes include magnesium chloride, sodium chloride, lithium chloride, potassium chloride, potassium sulfate, sodium carbonate, sodium sulfite, lithium sulfate, calcium bicarbonate, sodium sulfate, calcium sulfate, potassium acid phosphate, calcium lactate, magnesium succinate, tartaric acid, 20 soluble carbohydrates such as raffinose, glucose, lactose, mixtures thereof and the like. Of these, sodium chloride, potassium chloride, glucose and lactose are preferred. The solid solute can be in any suitable physical form such as particles, crystals, pellets, tablets, strips, film, granules and the like. However, from a manufacturing 25 standpoint, the osmotic agent 17 is preferably first compressed into a solid tablet, either as a homogenous single layer tablet or with a second layer 14 comprised of a rigid, non-dissolving material, prior to coating with the semipermeable membrane material.
.
` 30 The rate of liquid (e.g., water) influx per unit area of semipermeable membrane will depend upon the composition and thickness of the membrane and the magnitude of the osmotic imbalance (this assumes insignificant back pressure from the piston 24). In syringes that are used to administer a drug intravenously, the osmotic 35 pressure of the solute solution must exceed the blood pressure of the animal (about 10 kPa in humans). Sodium chloride is an especially - . . . ; . . ........... , . ~ . . . ......... .
. .
OSMOTICALLY DRIVEN SYRINGE
TECHNICAL FIELD
' s The invention pertains to a novel and useful osmotically driven syringe and in particular an implantable osmotically driven syringe.
The syringe delivers a beneficial agent, such as a drug, to an environment of use, such as an animal body.
,: ' ' o BACKGROUND ART
Over the past decade, much research has been devoted to developing new and useful devices for delivering beneficial agents to agent receptor environments of use. For example, in United States Patent No. 3,760,984 issued to Theeuwes, there is disclosed an osmotic delivery device comprising an inner collapsible container carrying on its outer surface a layer of an osmotic solute and a surrounding layer of a polymer permeable to fluid and impermeable to solute. In United States Patent No. 3,971,376, issued to Wichterle, ; 20 a device is disclosed comprising a capsule having a unitary wall `
formed of a substantially noncollapsible elastic material that maintains a constant volume and which is adapted to be implanted :.! subcutaneously.
' 25 In United States Patent No. 3,g87,790 issued to Eckenhoff et '~ al., there is dlsclosed another osmotic delivery device which contains an outer shape-retaining membrane which surrounds a solute ; layer which in turn surrounds a collapsible bag containing a liquid drug. Water from the exterior environment permeates through the .~ 30 outer membrane into the solute layer, causing the solute layer to swell. The swelling forces the bag to collapse and deliver the drug through a delivery orifice. United States Patent No. 3,995,631 issued to Higuchi et al., discloses a similar device (Figure 4) comprising an inner flexible bag containing a drug formulation. The 35 bag separates the drug from an osmotically effective solute material.
Both the drug and the solute are contained within a housing having an :' ~
. .
:. ''.
' ' ' ' ' , . ' ' : ' ' ` ' . ~ : . ` `: .:: ! : ' ' . ' , . . '. ' : ~ . ' . . ' ': ' ' . ' WO 93/00954 ~ PC~/US91/04684 exterior wall that is, at least in part, semipermeable. U.S. Patent No. 3,995,632 issued to Nakano et al discloses a similar device which incorporates a movable barrier within the housing. The barrier divides the housing into two compartments, one containing the solute s and the other containing the drug. The solute-containing compartment has an exterior wall that is, at least in part, semipermeable. The solute-containing compartment acts as an osmotic driver for the device.
~ lo U.S. Patent No. 4,410,328 issued to Theeuwes discloses an ; osmotically driven pump. The pump includes a housing 11 and a slidable piston 14 which divides the interior of the housing into two compartments. The first compartment contains a liquid drug 13 while the second compartment contains an osmotic driver 17. The osmotic s driver is a tablet of an osmotically effective solute, such as sodium chloride, which is coated with a semipermeable wall material. A
delivery orifice 20 is drilled through the semipermeable wall. The bottom surface of the osmotic driver 17 is exposed to water from the external environment. This can be done by incorporating a screen, or zo a plurality of holes through retaining member 18, immediately below the osmotic driver 17. Water from the external environment then contacts and is imbibed through the semipermeable wall 23 into the osmotic driver 17 to form a solution of the osmotic solute. As water continues to be imbibed through the semipermeable wall, the solution 2s in the driver is pumped through delivery orifice 20. The pumped solution eventually fills the space between the osmotic driver 17 and the bottom of piston 14. Thereafter, further pumping of solution from driver 17 forces piston 14 to more forward in housing ll. As the piston moves towards the opening 15, it urges a beneficial agent, 30 such as a drug, out of the compartment 13.
The device illustrated in U.S. Patent 4,410,328 has several potential disadvantages when used as an implantable pump. First, there is a substantial delay between the time when the osmotic driver : 3s 17 is exposed to the external aqueous environment (i.e., implanted in the body) and the time when the pump begins dispensing drug. This " .. . - . . . ~ . .
.
.. .. . . .... . .
: ~ : . . ' ' . ' ' ., ' , ' '' , . ' ' . . , :' , - . ~ . ~ , , ., .
.. . .. , . : ~ . , WO 93~00954 PCI/US91/04684 2~82~0~
delay is in part caused by the space surrounding the driver which must first be filled with solution pumped from the driver before the piston is forced to move forward. Secondly, only the bottom surface of osmotic driver 17 is exposed to the external aqueous environment.
s Because only a relatively small portion (i.e., about 25% or less) of the membrane surface area is exposed to the external aqueous environment, the rate at which water is imbibed through the semipermeable wall 23, and therefore the rate at which the drug is delivered by the pump, is difficult to control. This is especially critical with osmotically driven pumps which are implanted in an animal body. When implanted in certain animal tissues, portions of - the external surface of the pump will not be exposed to water. Thus, a dispensing device which utilizes an osmotic engine having only a small surface area of microporous and/or semipermeable membrane exposed will tend to have a greater degree of variability in its drug delivery rate since part or all of the membrane may not be exposed to aqueous body fluids.
.
While the above-described devices are useful for delivering : 20 many agents, and while they represent a valuable contribution to the delivery art, there has been a need in the art for an osmotically driven syringe which begins delivering a drug or other beneficial agent as soon as the syringe is placed in an aqueous environment (i.e., with a minimal lag time between the time when the syringe is 25 placed in the aqueous environment and the time when the syringe begins delivering the beneficial agent).
It is another object of the present invention to provide an osmotically driven syringe which can delivery a beneficial agent, 30 such as a drug, at a more uniform and more predictable delivery rate than was achieved by the osmotically driven syringes of the prior art.
In particular, it is an object of the present invention to 3s provide an osmotically driven syringe having the above-described .
.. . ~ .. . . . . , ............ , , . ....... ;, . . . . . ~
: ; . . . :~, ,, , ~ -2 ~
features and having a size making it suitable for implantation in an ~ animal body and in particular for implantation in a human body.
; DISCLOSURE OF THE INYENTION
The present invention provides an osmotically driven dispensing device for delivering a beneficial agent to an environment of use.
The device comprises a syringe having a chamber with a movable piston therein, the piston dividing the chamber into a beneficial agent-containing compartment and a driving compartment. The piston is movable into a position wherein the piston occupies substantially all of the driving compartment. The device includes an osmotic engine attached to the syringe adjacent the driving compartment. The osmotic engine comprises a shaped wall surrounding, and in contact with, an osmotic solute. The shaped wall has an external surface exposed to a fluid in an external environment and a passageway providing a fluid flow path between the osmotic solute and the driving compartment. The shaped wall is comprised of a material that is permeable to the external fluid and has a sufficient degree of 'I 20 impermeabillty to the solute to generate an osmotic pressuredifferential across the wall when exposed to the external fluid. At least about 30% of the wall which is in contact with the osmotic solute is also exposed to the external fluid. Preferably, at least about 50% of the wall which is in contact with the osmotic solute is 2s also exposed to the external fluid. Most preferably, substantially all of the wall which is in contact with the osmotic solute is also exposed to the external fluid.
Preferably, the osmotic engine comprises a shaped wall 30 surrounding a layer of an osmotically effective solute and a layer of a rigid non-dissolving material. The rigid non-dissolving layer provides support for the wall and maintains the wall shape adjacent the driving compartment. The wall preferably comprises a thin membrane that is permeable to the externa1 fluid (e.g., water) and .~ 3s substantially impermeable to the solute. A passageway is provided through both the wall and the rigid non-dissolving layer, thereby :
'.,;' ' '. '' ` ','.'. ~; ` ' ', ', ,- ,. ~ ~
:., , . . , . . , :
w o 93/00954 PCT/US91/0~684 ~23~
providing a fluid flow path between the osmotic solute layer and the driving compartment.
In operation, the external fluid is imbibed through the wall s into the osmotic engine forming a solution of the osmotic solute.
The solution is pumped through the passageway into the driving compartment as fresh fluid is imbibed through the wall. The pumped solution exerts pressure on the piston, forcing the piston to move within the syringe and deliver the beneficial agent from the o beneficial agent-containing compartment to the environment of use.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a cross sectional view of an osmotically driven s syringe utilizing a bilayered osmotic engine according to the present invention;
Figure Z is an enlarged cross sectional view of the osmotic engine shown in Figure li Figure 3 is a cross sectional view of a single layer osmotic engine suitable for use with the syringe illustrated in Figure 1;
Figure 4 is a cross sectional view of another embodiment of a 25 bilayered osmotic engine suitable for use according to the present invention;
i Figure 5 is a cross sectional view of the posterior end of an osmotically driven syringe utilizing the bilayered osmotic engine 30 illustrated in Figure 4;
Figure 6 is a graph showing the volume of a liquid beneficial agent delivered over a period of about 50 hours by an osmotically driven syringe utilizing the osmotic engine illustrated in Figure 3;
~s and .~ . ; .. : , ~ ` . . . . .. . . .
2 ~ ~ 2~ 6 Figure 7 is a graph showing the volume of a liquid beneficial agent delivered over a period of about 160 hours by an osmotically driven syringe utilizing the osmotic engine illustrated in Figure 2.
s In the drawings and specification, like parts in related Figures are identified by like numbers.
.: , MODES FOR CARRYING OUT THE INVENTION
" .
o Figure 1 of the drawings illustrates one example of a new and useful osmotically driven syringe for dispensing a liquid beneficial agent and Figures 2-4 illustrate three different embodiments of osmotic engine 10. Figure 4 illustrates another embodiment of a , bilayer osmotic engine which can be used with the syringe illustrated in Figure 5 having a cylindrically shaped housing.
The osmotic engine is designated in the Figures by the numeral 10. Osmotic engine 10 comprises a semipermeable or microporous wall 12 that encapsulates a tablet 16 of an osmotic agent represented by 17. A passageway 13 through semipermeable wall 12 provides a path for a solution of solute 17 to flow out of osmotic engine 10.
~ Referring to Figure 1, the syringe 20 is comprised of a housing h 22, which forms an interior chamber 21 having a movable piston 24 2s therein. The chamber 21 is divided by piston 24 into a beneficial agent-containing compartment 23 and a driving compartment 26. The piston 24 is movable into a position abutting against the engine 10, whereby the piston 24 occupies substantially all of the driving compartment 26. In this position the driving compartment 26 has an 30 "unoccupied" volume of essentially zero and the beneficial agent-containing compartment 23 has a maximum volume.
.'' The initial zero volume feature of compartment 26 has several benefits. First, the lag time for the syringe 20 to begin pumping 3s the beneficial agent from compartment 23 is minimized. This feature is important in those instances where it is desired to have syringe .,1 .
.
.` .
w o 93/00~54 PCT/US9l/0~684 7 ~ (~ ~ ~ n ~
20 begin delivering beneficial agent as soon as possible after the syringe 20 is placed in the fluid containing environment of use. The prior art osmotically driven pumps, such as the one disclosed in U.S.
Patent No. ~,410,328 typically had an initial lag period on the order s of about 10 to about 15 hours depending upon the size of the pump.
In the osmotically driven syringe of the present invention, the lag period has been reduced by about 70% thereby providing a lag period of only about 3 to about 5 hours for equivalently sized pumps/syringes. Second, compartment 26 contains substantially no o air. This is desirable because any air initially trapped in compartment 26 will cause a certain amount of pressure fluctuation on the piston 24 once osmotic engine I0 begins pumping solution. These pressure fluctuations cause variations in the delivery rate of syringe 20. Third, air initially trapped within chamber 26 creates a s potential hazard in intravenous drug delivery applications since the trapped air can leak into the beneficial agent-containing compartment 23. In the present invention, this potential ha~ard is e1iminated.
Syringe 20 also has a delivery port 25 which can be shaped to 20 accept a hypodermic needle, an IV catheter or the like. Piston 24 fits snugly against the internal surface of housing 22 and forms a fluid tight seal between compartment 23 and compartment 26. Piston ~
24 may be made of rubber, nylon, polytetrafluoroethylene and the :
like. Likewise, the housing 22 may be made from well known materials 25 such as metals or plastics that are inert relative to the liquids they contact and are nonirritating to an animal body. Examples of suitable materials include stainless steel, aluminum, polyolefins such as polypropylene and polyethylene, polyesters, polyamides, and polycarbonates. Of these, polypropylene is preferred.
The osmotic engine 10 is sealed within the posterior end portion 28 of syringe 20. The interior surface of end portion 28 is bevelled as shown in Figure 1. The osmotic engines 10 illustrated in Figure 2 and 3 are correspondingly shaped to closely fit against the 35 bevelled surface of end portion 28 and form a fluid tight seal therewith.
.: . . : ', ' ' - ' ' . 2 a ~ 8 Of course, it is within the scope of the present invention to utilize a syringe housing having other shapes. For instance, the interior surface of end portion 28 may be cylindrically shaped with no bevelling. As shown in Figure 5, the interion surface of end s portion 28 is threaded and adapted to receive a threaded cap 27.
The inner surface of cap 27 is cylindrically shaped to receive an osmotic engine 10 as shown in Figure 4 with the outer diameter of engine 10 closely approximating the inner diameter of cap 27. The osmotic engine 10 may be secured within cap 17 using an adhesive. An o 0-ring 29 may optionally be provided to ensure a fluid tight seal between cap 27 and syringe housing 22. Cap 27 may be made from the materials used to make housing 22 or the materials used to make membrane 12. Preferably, cap 27 is made from polystyrene, polyvinylchloride, polyacetal, polymethyl methacrylate~ cellulose acetate or cellulose acetate butyrate.
The osmotic engine 10 may be secured to the end portion 28 of syringe 20 (or to cap 27) by conventional means. For example, the osmotic engine 10 may be attached to housing 22 (or to cap 27) using 20 an adhesive which can adhere to the material used to construct the syringe (typically plastic) and the material used to form the semipermeable wall 12 (typically a cellulosic polymer). When utilizing a plastic housing 22 (or a plastic cap 27) and a cellulosic wall 12, pharmaceutically acceptable acrylic-based adhesives are 2s preferably used. It is important to orient osmotic engine 10 with the passageway 13 opening into compartment 26.
Wall 12 is preferably comprised of a membrane that possesses permeability to an external fluid such as water while simultaneously 30 possessing some degree of impermeability to osmotic agent 17, typically a salt or sugar. Wall 12 can be formed of a semipermeable material that has uniform properties across all its dimensions, that is, it is substantially imperforate or substantially homogenous.
Alternatively, wall 12 can be formed of a microporous material, that 3s is, a material having micropores or microholes. Furthermore, wall 12 can be formed of a material that is both semipermeable and WO 93/00954 PCI/US91/0~68~
9 2~2~
microporous, allowing an external fluid to permeate through while remaining substantially impermeable to osmotic agent 17. When wall 12 ls comprised of a material that is substantially imperforate, molecules of the external fluid dissolve in and diffuse through wall s 12 and into engine 10. When wall 12 is comprised of a microporous material, molecules of the external fluid migrate and diffuse into the micropores, then into engine 10. When wall 12 is comprised of a material having both of these properties, external fluid enters engine 10 by a concurrent operation of each of these mechanisms, that is, by osmosis through wall 12 and by diffusion through the pores of wall 12.
As shown in Figures 1 and 5, a portion of wall 12, the portion designated 12a, is exposed to the external environment while a second s portion of wall 12, designated 12b, is sealed within the syringe housing 22 and thus is not exposed to the external environment. As is clearly shcwn in Figures 1 and 5, the interior surfaces of wall portion 12a are in contact with the tablet 16 of osmotic agent 17.
In the most preferred embodiments illustrated in Figures 1 and 5, 20 substantially all of the wall portion 12a which is exposed to the external fluid is also in contact with the osmotic agent 17.
; ~owever, it is also within the scope of the present invention to utilize an osmotic engine in which at least 30% of the wall portion which is in contact with the osmotic solute along its interior 2s surface is also exposed to the external environment along its exterior surface. More preferably, at least about 50% of the wall portion which is in contact with the osmotic solute along its interior surface is also exposed to the external environment along its exterior surface. By maximizing the wall surface area exposed to 30 the external environment, the variability in the pumping rate of osmotic engine 10 is reduced.
Preferably, as shown in Figures 1, 2 and 4, the osmotic engine has a bilayered configuration including a layer of an osmotic : 3s agent 17 and a second layer 14 comprised of a rigid non-dissolving material. The layer 14 may be comprised of any rigid, non-dissolving .. . . . . . . . .
... .. .. . .
WO 93/00954 PCrIUS91/04684 ~ a ~ 2 ~ o material such as rigid plastics, ceramics, glasses and/or metals.
Preferably, layer 14 is comprised of a sterilizable, inert material.
Most preferably, layer 14 is comprised of a powdered material that becomes rigid after compression. Examples of non-dissolving powdered ; materials that become rigid after compression include powdered micropolyethylene wax and powdered calcium diphosphate. Generally, because the material forming layer 14 is non-dissolving, it will have little or no osmotic activity. In the most preferred embodiments shown in Figures 1 and 5, the wall portion 12b has an interior surface that is in direct contact with layer 14 and not in direct . contact with agent 17. On the other hand, substantially all of the wall portion 12a has an interior surface which is in contact with the osmotic agent 17. Thus in the most preferred embodiments illustrated in Figures 1 and 5, substantially all portions of wall 12 having an osmotic concentration gradient there-across, are also exposed to the exterior environment.
In the embodiment illustrated in Figure 3, the osmotic engine 10 has a single layer configuration. The osmotic agent 17, ; 20 optionally mixed with binders and/or buffers, is compressed to form atablet 16. The compression step may be performed in a conventional tablet making machine. The tablet 16 is then coated with a solution of a suitable semipermeable/microporous film forming material in accordance with known methods to form the semipermeable/microporous zs wall 12. Lastly, the passageway 13 is drilled into one side of osmotic engine 10 using a drill, laser or other known technique.
The b~layered osmotic engine 10 illustrated in Figures 1, 2, 4 and 5, may be formed by concurrently compressing a layer of a 30 suitable osmotic agent 17, optionally mixed with binders and/or buffers, and a layer 14 of a non-dissolving material which hardens upon compression. The compression step may be conducted in a conventional tablet making machine to form the bilayered tablet 16 having the structures illustrated in Figures 2 and 4. ~he bilayered 35 tablet 16 is then coated with a solution of a suitable semipermeable/
microporous film forming material in accordance with known methods to :
~82~"
form the semipermeable/microporous wall 12. Lastly, the passageway 13 is drilled into one side of osmotic engine 10 using a drill, laser or other known technique. When drilling a bilayered tablet 16, the passageway 13 is drilled in the side of the tablet 16 having the s rigid non-dissolving layer 14. It is important to drill the passageway 13 completely through layer 14 in order to provide an open fluid flow path which enables the solution of osmotic agent 17 to be pumped through passageway 13 to the drivjng compartment 26 of the syringe 20.
10 . .
Because layer 14 is composed of a rigid non-dissolving material, its structural integrity is not affected by the pumping of fluid through osmotic engine 10. As the agent 17 within osmotic engine 10 is dissolved, the layer 14 provides a rigid structural support for the wall portion 12b which is attached to syringe 20.
Thus, even as the active agent 17 is dissolved and pumped out of engine 10, the layer 14 retains its original shape and therefore wall portion 12b remains sealed to syringe 20.
.
Typical materials for forming wall 12 include synthetic or naturally occurring semipermeable and/or microporous membranes known to the art as osmosis and reverse osmosis membranes. Preferably, wall 12 is comprised of a cellulose ester. ~xamples of suitable membrane materials include commercially available unplasticized 25 cellulose acetate, plasticized cellulose acetate, reinforced cellulose acetate, cellulose nitrate with 11% nitrogen, cellulose diacetate, cellulose triacetate, agar acetate, amylose triacetate, beta glucan acetate, beta glucan triacetate, cellulose acetate, acetaldehyde dimethyl acetate, cellulose acetate ethyl carbamate, 30 cellulose acetate phthalate, cellulose acetate methyl carbamate, cellulose acetate succinate, cellulose acetate dimethaminoacetate, cellulose acetate ethyl carbonate, cellulose acetate chloroacetate, cellulose acetate ethyl oxalate, cellulose acetate methyl sulfonate, cellulose acetate butyl sulfonate, cellulose acetate propionate, 3s cellulose acetate p-toluene sulfonate, triacetate of locust gum bean, cellulose acetate with acetylated hydroxyethyl cellulose, WO 93/00954 PCr/US91/04684 2 ~
hydroxylated ethylene-vinylace~ate, cellulose acetate butyrate having a viscosity of from about 10 seconds to about 50 seconds, cellulose acetate butyrate containing about 17 percent o~ combined butyryl and about 29.5 percent acetyl, cellulose acylate, cellulose diacylate, s cellulose triacylate, permselective, aromatic nitrogen-containing polymeric membranes that exhibit water permeability and essentially no solute passage, osmosis membranes made from polymeric epoxides, osmosis membranes made from copolymers of an alkylene oxide and alkyl glycidyl ether, semipermeable polyurethanes, semipermeable o polyglycolic or polylactic acid and derivatives thereof, thin film membranes as disclosed by Loeb and Sourirajan in United States Patent No. 3,133,132, the membranes of ionically associated polyelectrolytes, the polymers formed by the coprecipitation of polycation and a polyanion as described in United States Patents 3,276,586; 3,541,005; 3,541,006; 3,546,142; 3,173,876; derivatives of polystyrene such as poly(sodium styrenesulfonate) and poly(vinylbenzyl^trimethyl-ammonium chloride), and the like. Wall 12 may also be formed from a microporous membrane such as polysulphone, polyvinyl chloride, polystyrene, nylon, polycarbonate, polymethyl 20 methacrylate, and other materials using soluble pore forming agents.
Generally, membranes having an osmotic fluid permeability of loB to 10~9 cm2/atm/hr against a saturated solute solution at the temperature ` of use while simultaneously possessing a sufficient degree of impermeability to the solute to generate an osmotic pressure 2s d~fferent1al across the membrane are useful and within the spirit of the invention.
Semipermeable wall 12 may also contain a wall forming pharmaceutically acceptable polymer or agent which acts as a 30 permeability enhancer to aid the passage of fluid into the osmotic engine 10. Representative of polymers and agents for the present purpose include water soluble and/or swellable polymers such as hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxyethyl ce~lulose, ethyl methylcellulose, methylcellulose, acrylics including 35 polyacrylic acid, polyethyl methacrylate, polymethyl methacrylate, . pyrrolidones including polyvinyl pyrrolidone, alkylated ' ~:
., .~, .
Wo 93/0095~ P~r/US91/04684 13 2~2'~,~Y`
vinylpyrrolidone polymers, poly(vinylpyrrolidone/vinyl acetate) copolymers, vinylpyrrolidone/dimethylamino-ethylmethacrylate copolymers, maleic acid polymers such as monobutyl ester of : poly(methyl vinylether/maleic acid), monoethyl ester of s poly(methylvinyl ether/maleic acid), poly(methylvinylether/~aleic anhydride) copolymer, polyvinyl alcohol hydrolyzed 75 to 85%, ~a~er soluble agents such as polyethylene glycol, polyethylene oxide, guar gum, gum arabic, dextran, citric acid, triethyl citrate, acetyltriethyl citrate, sucrose, fructose, glycerin, tria~etin, and o the like.
Various osmotically effective solutes which can be used as the osmotic agent 17 include solutes and hydrophilic polymers. Suitable hydrophilic polymers include those described in U.S. Patent No.
IS 4,327,775. Suitable solutes include magnesium chloride, sodium chloride, lithium chloride, potassium chloride, potassium sulfate, sodium carbonate, sodium sulfite, lithium sulfate, calcium bicarbonate, sodium sulfate, calcium sulfate, potassium acid phosphate, calcium lactate, magnesium succinate, tartaric acid, 20 soluble carbohydrates such as raffinose, glucose, lactose, mixtures thereof and the like. Of these, sodium chloride, potassium chloride, glucose and lactose are preferred. The solid solute can be in any suitable physical form such as particles, crystals, pellets, tablets, strips, film, granules and the like. However, from a manufacturing 25 standpoint, the osmotic agent 17 is preferably first compressed into a solid tablet, either as a homogenous single layer tablet or with a second layer 14 comprised of a rigid, non-dissolving material, prior to coating with the semipermeable membrane material.
.
` 30 The rate of liquid (e.g., water) influx per unit area of semipermeable membrane will depend upon the composition and thickness of the membrane and the magnitude of the osmotic imbalance (this assumes insignificant back pressure from the piston 24). In syringes that are used to administer a drug intravenously, the osmotic 35 pressure of the solute solution must exceed the blood pressure of the animal (about 10 kPa in humans). Sodium chloride is an especially - . . . ; . . ........... , . ~ . . . ......... .
. .
.
2 ~ 8 '~ 14 effective osmotic solute in that the osmotic pressure of sodium chloride is sufficiently high to remove the dependence of pumping rate on the osmotic pressure of the surrounding environment. By keeping the osmotic imbalance substantially constant, the influx of s liquid into osmotic engine 10 will be constant and so will both: (1) the rate of delivery of solution from osmotic engine 10 into compartment 26, and (2) the rate of delivery of the beneficial agent from compartment 23. Such operation is called "steady state" or ; "tonic" operation and is characterized by a controlled constant rate of deliYery at a predetermined baseline level.
In operation, the syringe 20 may be filled with a suitable beneficial agent by moving piston 24 with a plunger (not shown), thereby filling compartment 23 with a suitable dose of the beneficial agent. Agents that can be dispensed by syringe 20 include a wide range of drugs, antibacterials, antifungals, plant growth promoters, surfactants, chemical reactants, and the like. It is within the scope of the present invention to utilize a syringe 20 which has been prefilled with a dose of a liquid beneficial agent or which is filled 20 by the patient using a plunger which can be easily connected to piston 24 for drawing the dosage and which is easily disconnected from piston 24 once the appropriate dosage has been drawn.
Next, a suitable osmotic engine 10 is sealed within the end 2s portion 28 of syringe 20. Those skilled in the art will appreciate that the osmotic engine 10 can be selected to deliver beneficial agent at a predetermined pumping rate. The pumping rate of osmotic engine 10 can be varied, as is known in the art, by varying (1) the , composition of osmotic agent 17, (2) the composition of wall 12 and 30 (3) the sur~ace area of wall portion 12a exposed to the exterior ;
aqueous environment.
., .
The thus assembled syringe 20 may then be placed in an aqueous environment wherein the wall portion 12a is exposed to water. Water 3s from the aqueous environment is imbibed through the wall portion 12a into osmotic engine 10 where it forms a solution of the osmotic agent ...... . . . . ... . . . . . .
: . .. . : .. . ,. ~: ..... ~ . . . . .
WO 93/00~54 PCr/US91/04684 2 ~ 3 ~ ( 17. The imbibition of liquid, from either a fluid reservoir or an external environment such as an animal body, through wall portion 12a and into engine 10 is caused by an osmotic imbalance between the liquid and the composition of osmotic agent 17. As fresh liquid is s imbibed through wall portion 12a, the solution of osmotic agent 17 is "pumped" through passageway 13 and into the compartment 26. The pumping of solution from osmotic engine 10 forces piston 24 to move toward delivery port 25, thereby forcing the beneficial agent out of port 25.
`.`' 10 Alternatively, if the syringe 20 is to be used in a non-aqueous environment, for example as a portable non-implantable pump worn outside the body, a fluid reservoir container (not shown in the figures) may be attached to the end portion 28 of syringe 20 by conventional fastening means (e.g., screw threads) for supplying the necessary fluid needed to run the osmotic engine 10. When the reservoir container is fastened to end portion 28, the semipermeable : wall portion 12a of osmotic engine 10 is exposed to the fluid. The fluid reservoir container may also contain a wicking material, such 20 as a hydrogel or a sponge, which maintains the wall portion 12a continuously wetted by the reservoir fluid, regardless of the movement or physical orientation of the syringe/reservoir assembly.
The thus assembled syringe 20/reservoir may be secured, ~or example using straps or tape, on the patient with a needle or catheter (not 2s shown) penetratlng the cutaneous layer. Alternatively, the needle can be inserted into a vein and the syringe utilized as an IV
infusion device.
Alternatively, the fluid in compartment 23 may be inert and the 30 syringe 20 may be used simply as a displacement pump. In this embodiment the syringe 20 must be suitably interconnected by well known means to a reservoir of a fluid beneficial agent to be discharged, such that the inert fluid displaces the beneficial agent ` from the reservoir in a predetermined regimen to the desired -3s administratian site. Such alternatives are particularly attractive ~ .
.. . ... . . .. . . . .
,, ., , ,, .
., . .. -: , , .: ~ ...... . . ,: . ..
. ~ . . . - . . -. ~ . . .
WO 93/00954 PCl/US9ltO4684 2 ~ ('3 ~
in instances in which the beneficial agent is incompatible with housing 22.
The osmotically driven syringe of the present invention may be s used to deliver dosages having a fluid volume in a range of about 0.2 to about 20 cm3 oYer a period of about 0.5 to about 15 days.
Preferably, the syringe 20 has a size suitable for implanting in a human or other animal body. Implantable syringes have a compartment 23 which can typically hold from about 0.2 to 10 cm3 of a liquid beneficial agent. The osmotic engines useful in the osmotically driven syringe disclosed herein typically provide a delivery rate of about 0.1 to about 40 cm3/day.
The osmotically driven syringe 20 described herein is 15 particularly useful for the long-term administration of polypeptides such as insulin and buserelin, analgesics such as morphine sulfate, hydromorphone HCl, oxymorphone HCl, methadone HCl; anti-psychotics such as dihydroergotamine mesylate and promethazine HCl;
anti-asthmatics such as aminophylline and terbutaline sulfate;
20 anti-thrombotic agents such as heparin Na, urokinase and :
streptokinase; hormones such as corticotropin; anti-nausea agents such as metoclopramide HCl; anti-cancer drugs such as bleomycin sulfate, adriamycin, 5-fluorouracil and 5-fluorouracil deoxyribose;
antibiotics such as polymyxin B and amphotericin B; ion chelating " 2s agents such as deferoxamine mesylate; narcotic antagonists such as naloxone HCl; and ritodrine HCl.
.
Syringe 20 can be made as a disposable device for delivering a single dose of a beneficial agent. Alternatively, syringe 20 can be :-30 made as a reusable device. That is, agent compartment 23 can be refilled, osmotic engine 10 can be replaced with another engine having the same or a different pumping rate, and in the case of a nonimplantable pump, the fluid reservoir container can be refilled to ensure a continuous supply of the external fluid.
3s WO ~3/009~4 P~/US91/0468~
17 2û~2~
Having thus generally described the invention, the following examples will further illustrate preferred embodiments thereof.
' A standard 1 ml polypropylene syringe having a silicone rubber plunger was modified by beveling the interior surface of the posterior end of the syringe housing to the configuration shown in Figure 1. Two similar osmotic engines were constructed. Each o engine was formed by compressing 350 mg of powdered NaCl in a standard tablet making machine. The compressed salt tablet had the shape of tablet 16 illustrated in Figure 3 with a (largest) diameter of about 9 mm and a height of about 4 mm. The tablet was then spray ' coated with a solution of cellulose acetate in methylene chloride and- 15 methanol solvent. The coated tablet was then placed in an oven maintained at 50C for a period of 24 hours to evaporate off the residual solvent. The resulting membrane coating had a wall thickness of about 7 mils. A 25 mil fluid delivery passageway was drilled through the membrane wall. The osmotic engine was fastened 20 to the bevelled posterior end of the syringe using an acrylic-based adhesive.
. , .
; The agent-containing compartment was filled with water. With the agent-containing compartment filled, the plunger abutted against ,` 2s the osmotic englne and the driving compartment had substantially zero volume. A catheter was fastened to the delivery port of the syringe with the free end of the catheter leading to an empty graduated cylinder. The entire syringe was then submerged in water and the ; pumping of water from the syringe into the graduated cylinder was 30 monitored over a period of about 2 days. The volumetric fluid delivery profile of the syringe with each of the two osmotic engines was monitored over a period of about 2 days. The data is plotted in Figure 6. The syringe began pumping water about 3 hours after being submerged. Because the osmotic engine had no rigid non-dissolving 3s support layer (i.e., the engine had the configuration illustrated in Figure 3), the portions of the membrane surface area which were ' ~ . ' ' ~, . .
.:
.. . .. . .. ....
,; ,: , . . ~ .. . . . .
.
WO 93/009S'1 PCl/US91/04684 2 ~ ~ 2 ~
exposed to external water tended to expand slightly during operation, resulting in a slight increase in the delivery rate after about 30 hours.
';
s EXAMPLE 2 The syringe used in Example 1 was tested with two similar osmotic engines having a bilayered configuration as shown in Figure 2. Each of the osmotic engines was formed by concurrently : lo compressing a layer containing 175 mg of powdered micropolyethylene ~ wax (Fischer-Tropsch wax having a particle size in the range of 1-3 - um) and a layer containing 175 mg of NaCl. Upon compression, the ~ -micropolyethylene wax layer became hardened. The compressed bilayered tablet was then coated with a solution of cellulose acetate s and dried in accordance with the procedures described above in Example 1. The membrane wall had a thickness of about 7 mils. A 25 mil fluid delivery passageway was drilled through the membrane wall and the polyethylene wax layer. The osmotic engine was then fastened to the bevelled posterior end of the syringe using an acrylic-based 20 adhesive.
.. . . .
The fluid delivery profile of the syringe was then tested in accordance with the same procedures described above in Example 1.
The volumetric fluid delivery profile of the syringe with each of the 2s two osmotic engines was monitored over a period of about seven days.
The data is plotted in Figure 7. The syringe began pumping water about 10 hours after being submerged. The delay period (10 hours) for this engine was longer than the delay period (3 hours) for the engine tested in Example 1. The longer delay was due in part to the 30 lower pumping rate for this engine. Because the engine had a rigid non-dissolving internal support layer, the membrane surface area which was exposed to the external water was maintained substantially constant (i.e., no expansion of the membrane) resulting in a more uniform pumping rate as shown in Figure 7.
3s .~, - ' `, .
. ~ ~
. .~ . .
'~ . ' '. i ' ' ` ': , ' , !.` , ' . " ' : . . . .
: ~
2 ~ ~, 2 ~
While certain preferred embodiments of the present have been selected for illustration in the drawings and have been described in detail herein, the illustrated embodiments should not be construed as : limiting and those skilled in the art will appreciate that various s modifications, changes and additions to the illustrated embodiments may be made without departing from the spirit and scope of the present invention as defined in the appended claims.
. .
-:~ ~ .,: . ............................. .
,,
2 ~ 8 '~ 14 effective osmotic solute in that the osmotic pressure of sodium chloride is sufficiently high to remove the dependence of pumping rate on the osmotic pressure of the surrounding environment. By keeping the osmotic imbalance substantially constant, the influx of s liquid into osmotic engine 10 will be constant and so will both: (1) the rate of delivery of solution from osmotic engine 10 into compartment 26, and (2) the rate of delivery of the beneficial agent from compartment 23. Such operation is called "steady state" or ; "tonic" operation and is characterized by a controlled constant rate of deliYery at a predetermined baseline level.
In operation, the syringe 20 may be filled with a suitable beneficial agent by moving piston 24 with a plunger (not shown), thereby filling compartment 23 with a suitable dose of the beneficial agent. Agents that can be dispensed by syringe 20 include a wide range of drugs, antibacterials, antifungals, plant growth promoters, surfactants, chemical reactants, and the like. It is within the scope of the present invention to utilize a syringe 20 which has been prefilled with a dose of a liquid beneficial agent or which is filled 20 by the patient using a plunger which can be easily connected to piston 24 for drawing the dosage and which is easily disconnected from piston 24 once the appropriate dosage has been drawn.
Next, a suitable osmotic engine 10 is sealed within the end 2s portion 28 of syringe 20. Those skilled in the art will appreciate that the osmotic engine 10 can be selected to deliver beneficial agent at a predetermined pumping rate. The pumping rate of osmotic engine 10 can be varied, as is known in the art, by varying (1) the , composition of osmotic agent 17, (2) the composition of wall 12 and 30 (3) the sur~ace area of wall portion 12a exposed to the exterior ;
aqueous environment.
., .
The thus assembled syringe 20 may then be placed in an aqueous environment wherein the wall portion 12a is exposed to water. Water 3s from the aqueous environment is imbibed through the wall portion 12a into osmotic engine 10 where it forms a solution of the osmotic agent ...... . . . . ... . . . . . .
: . .. . : .. . ,. ~: ..... ~ . . . . .
WO 93/00~54 PCr/US91/04684 2 ~ 3 ~ ( 17. The imbibition of liquid, from either a fluid reservoir or an external environment such as an animal body, through wall portion 12a and into engine 10 is caused by an osmotic imbalance between the liquid and the composition of osmotic agent 17. As fresh liquid is s imbibed through wall portion 12a, the solution of osmotic agent 17 is "pumped" through passageway 13 and into the compartment 26. The pumping of solution from osmotic engine 10 forces piston 24 to move toward delivery port 25, thereby forcing the beneficial agent out of port 25.
`.`' 10 Alternatively, if the syringe 20 is to be used in a non-aqueous environment, for example as a portable non-implantable pump worn outside the body, a fluid reservoir container (not shown in the figures) may be attached to the end portion 28 of syringe 20 by conventional fastening means (e.g., screw threads) for supplying the necessary fluid needed to run the osmotic engine 10. When the reservoir container is fastened to end portion 28, the semipermeable : wall portion 12a of osmotic engine 10 is exposed to the fluid. The fluid reservoir container may also contain a wicking material, such 20 as a hydrogel or a sponge, which maintains the wall portion 12a continuously wetted by the reservoir fluid, regardless of the movement or physical orientation of the syringe/reservoir assembly.
The thus assembled syringe 20/reservoir may be secured, ~or example using straps or tape, on the patient with a needle or catheter (not 2s shown) penetratlng the cutaneous layer. Alternatively, the needle can be inserted into a vein and the syringe utilized as an IV
infusion device.
Alternatively, the fluid in compartment 23 may be inert and the 30 syringe 20 may be used simply as a displacement pump. In this embodiment the syringe 20 must be suitably interconnected by well known means to a reservoir of a fluid beneficial agent to be discharged, such that the inert fluid displaces the beneficial agent ` from the reservoir in a predetermined regimen to the desired -3s administratian site. Such alternatives are particularly attractive ~ .
.. . ... . . .. . . . .
,, ., , ,, .
., . .. -: , , .: ~ ...... . . ,: . ..
. ~ . . . - . . -. ~ . . .
WO 93/00954 PCl/US9ltO4684 2 ~ ('3 ~
in instances in which the beneficial agent is incompatible with housing 22.
The osmotically driven syringe of the present invention may be s used to deliver dosages having a fluid volume in a range of about 0.2 to about 20 cm3 oYer a period of about 0.5 to about 15 days.
Preferably, the syringe 20 has a size suitable for implanting in a human or other animal body. Implantable syringes have a compartment 23 which can typically hold from about 0.2 to 10 cm3 of a liquid beneficial agent. The osmotic engines useful in the osmotically driven syringe disclosed herein typically provide a delivery rate of about 0.1 to about 40 cm3/day.
The osmotically driven syringe 20 described herein is 15 particularly useful for the long-term administration of polypeptides such as insulin and buserelin, analgesics such as morphine sulfate, hydromorphone HCl, oxymorphone HCl, methadone HCl; anti-psychotics such as dihydroergotamine mesylate and promethazine HCl;
anti-asthmatics such as aminophylline and terbutaline sulfate;
20 anti-thrombotic agents such as heparin Na, urokinase and :
streptokinase; hormones such as corticotropin; anti-nausea agents such as metoclopramide HCl; anti-cancer drugs such as bleomycin sulfate, adriamycin, 5-fluorouracil and 5-fluorouracil deoxyribose;
antibiotics such as polymyxin B and amphotericin B; ion chelating " 2s agents such as deferoxamine mesylate; narcotic antagonists such as naloxone HCl; and ritodrine HCl.
.
Syringe 20 can be made as a disposable device for delivering a single dose of a beneficial agent. Alternatively, syringe 20 can be :-30 made as a reusable device. That is, agent compartment 23 can be refilled, osmotic engine 10 can be replaced with another engine having the same or a different pumping rate, and in the case of a nonimplantable pump, the fluid reservoir container can be refilled to ensure a continuous supply of the external fluid.
3s WO ~3/009~4 P~/US91/0468~
17 2û~2~
Having thus generally described the invention, the following examples will further illustrate preferred embodiments thereof.
' A standard 1 ml polypropylene syringe having a silicone rubber plunger was modified by beveling the interior surface of the posterior end of the syringe housing to the configuration shown in Figure 1. Two similar osmotic engines were constructed. Each o engine was formed by compressing 350 mg of powdered NaCl in a standard tablet making machine. The compressed salt tablet had the shape of tablet 16 illustrated in Figure 3 with a (largest) diameter of about 9 mm and a height of about 4 mm. The tablet was then spray ' coated with a solution of cellulose acetate in methylene chloride and- 15 methanol solvent. The coated tablet was then placed in an oven maintained at 50C for a period of 24 hours to evaporate off the residual solvent. The resulting membrane coating had a wall thickness of about 7 mils. A 25 mil fluid delivery passageway was drilled through the membrane wall. The osmotic engine was fastened 20 to the bevelled posterior end of the syringe using an acrylic-based adhesive.
. , .
; The agent-containing compartment was filled with water. With the agent-containing compartment filled, the plunger abutted against ,` 2s the osmotic englne and the driving compartment had substantially zero volume. A catheter was fastened to the delivery port of the syringe with the free end of the catheter leading to an empty graduated cylinder. The entire syringe was then submerged in water and the ; pumping of water from the syringe into the graduated cylinder was 30 monitored over a period of about 2 days. The volumetric fluid delivery profile of the syringe with each of the two osmotic engines was monitored over a period of about 2 days. The data is plotted in Figure 6. The syringe began pumping water about 3 hours after being submerged. Because the osmotic engine had no rigid non-dissolving 3s support layer (i.e., the engine had the configuration illustrated in Figure 3), the portions of the membrane surface area which were ' ~ . ' ' ~, . .
.:
.. . .. . .. ....
,; ,: , . . ~ .. . . . .
.
WO 93/009S'1 PCl/US91/04684 2 ~ ~ 2 ~
exposed to external water tended to expand slightly during operation, resulting in a slight increase in the delivery rate after about 30 hours.
';
s EXAMPLE 2 The syringe used in Example 1 was tested with two similar osmotic engines having a bilayered configuration as shown in Figure 2. Each of the osmotic engines was formed by concurrently : lo compressing a layer containing 175 mg of powdered micropolyethylene ~ wax (Fischer-Tropsch wax having a particle size in the range of 1-3 - um) and a layer containing 175 mg of NaCl. Upon compression, the ~ -micropolyethylene wax layer became hardened. The compressed bilayered tablet was then coated with a solution of cellulose acetate s and dried in accordance with the procedures described above in Example 1. The membrane wall had a thickness of about 7 mils. A 25 mil fluid delivery passageway was drilled through the membrane wall and the polyethylene wax layer. The osmotic engine was then fastened to the bevelled posterior end of the syringe using an acrylic-based 20 adhesive.
.. . . .
The fluid delivery profile of the syringe was then tested in accordance with the same procedures described above in Example 1.
The volumetric fluid delivery profile of the syringe with each of the 2s two osmotic engines was monitored over a period of about seven days.
The data is plotted in Figure 7. The syringe began pumping water about 10 hours after being submerged. The delay period (10 hours) for this engine was longer than the delay period (3 hours) for the engine tested in Example 1. The longer delay was due in part to the 30 lower pumping rate for this engine. Because the engine had a rigid non-dissolving internal support layer, the membrane surface area which was exposed to the external water was maintained substantially constant (i.e., no expansion of the membrane) resulting in a more uniform pumping rate as shown in Figure 7.
3s .~, - ' `, .
. ~ ~
. .~ . .
'~ . ' '. i ' ' ` ': , ' , !.` , ' . " ' : . . . .
: ~
2 ~ ~, 2 ~
While certain preferred embodiments of the present have been selected for illustration in the drawings and have been described in detail herein, the illustrated embodiments should not be construed as : limiting and those skilled in the art will appreciate that various s modifications, changes and additions to the illustrated embodiments may be made without departing from the spirit and scope of the present invention as defined in the appended claims.
. .
-:~ ~ .,: . ............................. .
,,
Claims (18)
1. An osmotically driven dispensing device for delivering a beneficial agent to an environment of use, the device comprising:
a) a syringe having a chamber with a movable piston therein, the piston dividing the chamber into a beneficial agent-containing compartment and a driving compartment, the piston being movable into a position wherein the piston occupies substantially all of the driving compartment;
b) an osmotic engine attached to the syringe adjacent the driving compartment, the engine comprising a shaped wall surrounding, and in contact with, an osmotic solute, the wall having an external surface exposed to a fluid in an external environment, and a passageway providing a fluid flow path between the osmotic solute and the driving compartment, the wall being comprised of a material that is permeable to the external fluid and having a sufficient degree of impermeability to the solute to generate an osmotic pressure differential across the wall when exposed to the external fluid, at least about 30% of the wall which is in contact with the osmotic solute also being exposed to the external environment;
wherein in operation, the external fluid is imbibed through the wall into the osmotic engine to form a solution of the osmotic solute, the solution being pumped through the passageway into the driving compartment as fresh fluid is imbibed through the wall, thereby exerting pressure on the piston and forcing the piston to move within the syringe chamber and deliver the beneficial agent from the beneficial agent-containing compartment to the environment of use.
a) a syringe having a chamber with a movable piston therein, the piston dividing the chamber into a beneficial agent-containing compartment and a driving compartment, the piston being movable into a position wherein the piston occupies substantially all of the driving compartment;
b) an osmotic engine attached to the syringe adjacent the driving compartment, the engine comprising a shaped wall surrounding, and in contact with, an osmotic solute, the wall having an external surface exposed to a fluid in an external environment, and a passageway providing a fluid flow path between the osmotic solute and the driving compartment, the wall being comprised of a material that is permeable to the external fluid and having a sufficient degree of impermeability to the solute to generate an osmotic pressure differential across the wall when exposed to the external fluid, at least about 30% of the wall which is in contact with the osmotic solute also being exposed to the external environment;
wherein in operation, the external fluid is imbibed through the wall into the osmotic engine to form a solution of the osmotic solute, the solution being pumped through the passageway into the driving compartment as fresh fluid is imbibed through the wall, thereby exerting pressure on the piston and forcing the piston to move within the syringe chamber and deliver the beneficial agent from the beneficial agent-containing compartment to the environment of use.
2. The device of claim 1, wherein the osmotic engine comprises a shaped wall surrounding a layer of an osmotically effective solute, the shaped wall also surrounding a layer of a rigid, non-dissolving material, the rigid material providing a rigid support for the shaped wall in order to fixedly attach the osmotic engine to the syringe.
3. The device of claim 2, wherein the passageway extends through both the wall and the rigid, non-dissolving layer to provide a fluid flow path between the osmotic solute and the driving compartment.
4. The device of claim 2, wherein the rigid, non-dissolving layer is comprised of a material selected from the group consisting of rigid plastics, metals, ceramics and glasses.
5. The device of claim 4, wherein the rigid, non-dissolving layer is comprised of micropolyethylene wax.
6. The device of claim 1, wherein the syringe is comprised of plastic.
7. The device of claim 6, wherein the plastic comprises polypropylene.
8. The device of claim 1, wherein the semipermeable wall material is comprised of a cellulose ester.
9. The device of claim 1, wherein the cellulose ester is selected from the group consisting of cellulose acetate and cellulose acetate butyrate.
10. The device of claim 1, wherein the external fluid comprises water.
11. The device of claim 1, wherein the osmotically effective solute is selected from the group consisting of sodium chloride, potassium chloride, glucose, lactose and hydrophilic polymers.
12. The device of claim 1, wherein the osmotic engine is adhered to the syringe.
13. The device of claim 12, wherein the osmotic engine is adhered to the syringe using an acrylic-based adhesive.
14. The device of claim 1, wherein at least 50% of the wall which is in contact with the osmotic solute is also exposed to the external environment.
15. device of claim 1, wherein substantially all of the wall which is in contact with the osmotic solute is also exposed to the external environment.
16. The device of claim 1, wherein the beneficial agent-containing compartment contains a liquid beneficial agent.
17. The device of claim 1, wherein the beneficial agent-containing compartment has a maximum volume when the volume of the driving compartment is essentially zero.
18. The device of claim 1, wherein the environment of use is within an animal body.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/451,476 US5030216A (en) | 1989-12-15 | 1989-12-15 | Osmotically driven syringe |
PCT/US1991/004684 WO1993000954A1 (en) | 1989-12-15 | 1991-07-01 | Osmotically driven syringe |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2082808A1 true CA2082808A1 (en) | 1993-01-02 |
Family
ID=23792371
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002082808A Abandoned CA2082808A1 (en) | 1989-12-15 | 1991-07-01 | Osmotically driven syringe |
Country Status (3)
Country | Link |
---|---|
US (1) | US5030216A (en) |
CA (1) | CA2082808A1 (en) |
WO (1) | WO1993000954A1 (en) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5135523A (en) * | 1988-12-13 | 1992-08-04 | Alza Corporation | Delivery system for administering agent to ruminants and swine |
US5728088A (en) * | 1988-12-13 | 1998-03-17 | Alza Corporation | Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals |
US5234424A (en) * | 1988-12-28 | 1993-08-10 | Alza Corporation | Osmotically driven syringe |
US5222362A (en) * | 1989-01-10 | 1993-06-29 | Maus Daryl D | Heat-activated drug delivery system and thermal actuators therefor |
US5151093A (en) * | 1990-10-29 | 1992-09-29 | Alza Corporation | Osmotically driven syringe with programmable agent delivery |
US5201728A (en) * | 1991-05-03 | 1993-04-13 | Giampapa Vincent C | Subcutaneous implantable multiple-agent delivery system |
US5391164A (en) * | 1991-05-03 | 1995-02-21 | Giampapa; Vincent C. | Subcutaneous implantable multiple-agent delivery system |
US5403595A (en) * | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5221278A (en) * | 1992-03-12 | 1993-06-22 | Alza Corporation | Osmotically driven delivery device with expandable orifice for pulsatile delivery effect |
US5780051A (en) * | 1992-04-02 | 1998-07-14 | Dynagen, Inc. | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use |
US5242910A (en) * | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
US5447725A (en) * | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
US5540665A (en) * | 1994-01-31 | 1996-07-30 | Alza Corporation | Gas driven dispensing device and gas generating engine therefor |
US5837276A (en) | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
US5582591A (en) * | 1994-09-02 | 1996-12-10 | Delab | Delivery of solid drug compositions |
US5549636A (en) * | 1994-10-05 | 1996-08-27 | Li Medical Technologies Inc. | Surgical grasper with articulated fingers |
US5562654A (en) * | 1994-10-28 | 1996-10-08 | University Of Kentucky Research Foundation | Time-released delivery system |
US5651979A (en) * | 1995-03-30 | 1997-07-29 | Gel Sciences, Inc. | Apparatus and method for delivering a biologically active compound into a biological environment |
US5690952A (en) * | 1995-06-07 | 1997-11-25 | Judy A. Magruder et al. | Implantable system for delivery of fluid-sensitive agents to animals |
PL335420A1 (en) * | 1997-02-24 | 2000-04-25 | Willuweit Thomas | Apparatus for meteringly dispensing liquid substances |
US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
GB2347081A (en) * | 1999-02-23 | 2000-08-30 | William Leslie Porter | Device for supplying a beneficial substance to an animal |
DE60023361T2 (en) | 1999-12-21 | 2006-04-27 | Alza Corp., Mountain View | VALVE FOR OSMOTIC DEVICES |
US6464688B1 (en) | 2000-02-15 | 2002-10-15 | Microsolutions, Inc. | Osmotic pump delivery system with flexible drug compartment |
AU2007202144B2 (en) * | 2000-11-29 | 2009-04-23 | Durect Corporation | Devices and methods for controlled delivery from a drug delivery device |
US6632217B2 (en) * | 2001-04-19 | 2003-10-14 | Microsolutions, Inc. | Implantable osmotic pump |
US7896867B2 (en) * | 2002-05-01 | 2011-03-01 | Microlin, Llc | Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method |
US7470267B2 (en) * | 2002-05-01 | 2008-12-30 | Microlin, Llc | Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method |
US7458965B2 (en) * | 2002-05-01 | 2008-12-02 | Microlin, Llc | Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method |
US20060116663A1 (en) * | 2002-05-01 | 2006-06-01 | Joshi Ashok V | Electro-osmotic fluid delivery device and method |
ATE376854T1 (en) * | 2002-06-26 | 2007-11-15 | Alza Corp | MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
JP2006521897A (en) * | 2003-03-31 | 2006-09-28 | アルザ・コーポレーション | Osmotic pump with means for dissipating internal pressure |
US7371228B2 (en) | 2003-09-19 | 2008-05-13 | Medtronic Vascular, Inc. | Delivery of therapeutics to treat aneurysms |
US7897378B2 (en) * | 2004-03-18 | 2011-03-01 | Roche Molecular Systems, Inc. | Method and device for purifying nucleic acids |
US9788978B2 (en) * | 2004-12-20 | 2017-10-17 | Nicholas A. Rojo | Implantable systems and stents containing cells for therapeutic uses |
CA2592922A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US8348930B2 (en) * | 2005-07-01 | 2013-01-08 | Microlin, Llc | Fluid delivery device with a diffusion membrane and electrochemical pump |
US20070025869A1 (en) * | 2005-07-15 | 2007-02-01 | Gordon John H | Fluid Delivery Device |
CN101453982B (en) | 2006-05-30 | 2011-05-04 | 精达制药公司 | Two-piece, internal-channel osmotic delivery system flow modulator |
ES2422864T3 (en) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
US20080147186A1 (en) * | 2006-12-14 | 2008-06-19 | Joshi Ashok V | Electrochemical Implant For Delivering Beneficial Agents |
US9895494B2 (en) | 2007-01-25 | 2018-02-20 | DePuy Synthes Products, Inc. | Syringe with energy delivery component and method of use |
RU2440097C2 (en) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
US20090235689A1 (en) * | 2008-03-21 | 2009-09-24 | Christopher Designs, Inc. | Gemstone jewelry with enhanced appearance |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US20130090633A1 (en) * | 2011-10-07 | 2013-04-11 | University Of Southern California | Osmotic patch pump |
EP3143988A1 (en) | 2013-03-14 | 2017-03-22 | Fresenius Kabi Deutschland GmbH | Injectable morphine formulations |
AU2014230836C1 (en) | 2013-03-14 | 2018-12-20 | Fresenius Kabi Deutschland Gmbh | Packaging system for oxygen-sensitive drugs |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
EP3302354B1 (en) | 2015-06-03 | 2023-10-04 | i2o Therapeutics, Inc. | Implant placement systems |
WO2017200943A1 (en) | 2016-05-16 | 2017-11-23 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
CN106871677A (en) * | 2017-02-21 | 2017-06-20 | 联想(北京)有限公司 | A kind of heat pipe, radiator and electronic equipment |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
CN109589491B (en) * | 2019-01-29 | 2024-01-09 | 上海安翰医疗技术有限公司 | Automatic drug delivery device |
US11672992B2 (en) * | 2019-05-29 | 2023-06-13 | Pacesetter, Inc. | Valves for use in manufacturing of implantable medical devices |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (en) * | 1960-11-29 | |||
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3995631A (en) * | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US3732865A (en) * | 1971-01-13 | 1973-05-15 | Alza Corp | Osmotic dispenser |
US3760984A (en) * | 1971-09-29 | 1973-09-25 | Alza Corp | Osmotically powered agent dispensing device with filling means |
US3971376A (en) * | 1973-02-26 | 1976-07-27 | Ceskoslovenska Akademie Ved | Method and apparatus for introducing fluids into the body |
US3995632A (en) * | 1973-05-04 | 1976-12-07 | Alza Corporation | Osmotic dispenser |
US3946734A (en) * | 1975-02-19 | 1976-03-30 | The United States Of America As Represented By The Secretary Of State | Apparatus for controlling the release of a drug |
US3987790A (en) * | 1975-10-01 | 1976-10-26 | Alza Corporation | Osmotically driven fluid dispenser |
DE2721752C2 (en) * | 1977-05-13 | 1983-12-29 | Siemens AG, 1000 Berlin und 8000 München | Device implantable in a human or animal body for the infusion of a medical liquid |
US4320758A (en) * | 1979-05-07 | 1982-03-23 | Alza Corporation | Osmotically driven fluid dispenser |
US4327725A (en) * | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US4410328A (en) * | 1981-07-10 | 1983-10-18 | Alza Corporation | Dispensing device with internal drive |
US4474575A (en) * | 1982-02-01 | 1984-10-02 | Alza Corporation | Self-driven pump assembly and method of operation |
US4539004A (en) * | 1982-09-22 | 1985-09-03 | Alza Corporation | Self-driven pump assembly and method of operation |
US4723958A (en) * | 1986-05-23 | 1988-02-09 | Merck & Co., Inc. | Pulsatile drug delivery system |
US4838862A (en) * | 1986-08-04 | 1989-06-13 | Pharmetrix Corp. | Portable controlled release osmotic infusion device |
US4874388A (en) * | 1987-06-25 | 1989-10-17 | Alza Corporation | Multi-layer delivery system |
US4929233A (en) * | 1988-08-26 | 1990-05-29 | Alza Corporation | Implantable fluid imbibing pump with improved closure |
US4969884A (en) * | 1988-12-28 | 1990-11-13 | Alza Corporation | Osmotically driven syringe |
-
1989
- 1989-12-15 US US07/451,476 patent/US5030216A/en not_active Expired - Fee Related
-
1991
- 1991-07-01 CA CA002082808A patent/CA2082808A1/en not_active Abandoned
- 1991-07-01 WO PCT/US1991/004684 patent/WO1993000954A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO1993000954A1 (en) | 1993-01-21 |
US5030216A (en) | 1991-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5030216A (en) | Osmotically driven syringe | |
US4969884A (en) | Osmotically driven syringe | |
US5234424A (en) | Osmotically driven syringe | |
US5151093A (en) | Osmotically driven syringe with programmable agent delivery | |
US4439196A (en) | Osmotic drug delivery system | |
EP0259013B1 (en) | Portable controlled release osmotic infusion device | |
US4475916A (en) | Osmotic drug delivery system | |
US4898582A (en) | Portable infusion device assembly | |
KR100600462B1 (en) | Osmotic delivery system plug, osmotic delivery system, method of controlling a delivery rate of a beneficial agent from an osmotic drug delivery system, and method of changing a liquid permeation rate through a semipermeable body of an osmotic delivery system | |
ES2378675T3 (en) | Delivery system of a beneficial agent with a sealing membrane | |
US4609374A (en) | Osmotic device comprising means for governing initial time of agent release therefrom | |
EP0089548A1 (en) | Osmotic drug delivery system | |
US3760984A (en) | Osmotically powered agent dispensing device with filling means | |
US4976966A (en) | Delayed release osmotically driven fluid dispenser | |
ES2226159T3 (en) | FLOW MODULATOR DEVICE FOR OSMOTIC RELEASE SYSTEM. | |
US4511352A (en) | Parenteral delivery system with in-line container | |
US5169390A (en) | Osmotic infusion device | |
JP3058738B2 (en) | Osmotic pump | |
US4871352A (en) | Self-regulated therapeutic agent delivery system and method | |
KR20050120767A (en) | Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems | |
WO1994005354A1 (en) | Fluid driven dispensing device | |
IE912295A1 (en) | Osmotically driven syringe | |
PT98170A (en) | Osmotically actuated syringe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |